Significant improvement of refractory cutaneous lesions of lupus erythematosus with the use of anifrolumab: a report of two cases

Anifrolumab, a monoclonal antibody targeting the interferon-1 receptor, is currently approved for the treatment of moderate- to-severe systemic lupus erythematosus, but emerging evidence highlights its potential efficacy in cases with predominant cutaneous involvement. We present two cases illustrat...

Full description

Bibliographic Details

Published in:	Revista da Sociedade Portuguesa de Dermatologia e Venereologia
Main Authors:	Gilberto P. da Rosa, Isabel Antunes, Bárbara V. Granja, Patrícia Gomes, Rúben Costa, Filomena Azevedo, Alberto Mota
Format:	Article
Language:	English
Published:	Sociedade Portuguesa de Dermatologia e Venereologia 2025-07-01
Subjects:	Cutaneous lupus erythematosus. Discoid lupus erythematosus. Anifrolumab. Subacute cutaneous lupus erythematosus.
Online Access:	https://www.portuguesejournalofdermatology.com/frame_eng.php?id=265